The impact of gut microbiome-targeted therapy on liver enzymes in patients with nonalcoholic fatty liver disease: an umbrella meta-analysis
The DOI matches its Crossref record; 95 of the 96 references it cites were found in a registry or an index.
Abstract
Context: Nonalcoholic fatty liver disease (NAFLD) is considered the leading cause of chronic liver disease worldwide. To date, no confirmed medication is available for the treatment of NAFLD. Previous studies showed the promising effects of gut microbiome–targeted therapies; however, the results were controversial and the strength of the evidence and their clinical significance remained unclear. Objectives: This umbrella study summarizes the results of meta-analyses investigating the effects of probiotics, prebiotics, and synbiotics on liver enzymes in the NAFLD population. Data Source: A comprehensive search of the PubMed, Scopus, Web of Science, and Cochrane Library databases was done up to December 20, 2022, to find meta-analyses on randomized control trials reporting the effects of gut microbial therapy on patients with NAFLD. Data Extraction: Two independent investigators extracted data on the characteristics of meta-analyses, and any discrepancies were resolved by a third researcher. The AMSTAR2 checklist was used for evaluating the quality of studies. Data Analysis: A final total of 15 studies were included in the analysis. Results showed that microbiome-targeted therapies could significantly reduce levels of alanine aminotransferase (ALT; effect size [ES], −10.21; 95% confidence interval [CI], −13.29, −7.14; P < 0.001), aspartate aminotransferase (AST; ES, −8.86; 95%CI, −11.39, −6.32; P < 0.001), and γ-glutamyltransferase (ES, −5.56; 95%CI, −7.92, −3.31; P < 0.001) in patients with NAFLD. Results of subgroup analysis based on intervention showed probiotics could significantly reduce levels of AST (ES, −8.69; 95%CI, −11.01, −6.37; P < 0.001) and ALT (ES, −9.82; 95%CI, −11.59, −8.05; P < 0.001). Synbiotics could significantly reduce levels of AST (ES, −11.40; 95%CI, −13.91, −8.88; P < 0.001) and ALT (ES, −11.87; 95%CI, −13.80, −9.95; P < 0.001). Prebiotics had no significant effects on AST and ALT levels (ES, −2.96; 95%CI, −8.12, 2.18, P = 0.259; and ES, −4.69; 95%CI, −13.53, 4.15, P = 0.299, respectively). Conclusion: Gut microbiome–targeted therapies could be a promising therapeutic approach in the improvement of hepatic damage in patients with NAFLD. However, more studies are needed to better determine the best bacterial strains, duration of treatment, and optimum dosage of gut microbiome–targeted therapies in the treatment of the NAFLD population. Systematic Review Registration: PROSPERO registration no. CRD42022346998.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Gut microbial therapy by administration of probiotics, synbiotics and prebiotics may alleviate the medical condition in specific disorders, for example reduction of C-reactive protein50, low-density lipoprotein (LDL)51, alanine aminotransferase and aspartate aminotransferase52 and insulin resistance53 among non-alcoholic fatty liver disease (NAFLD).”
From Association between attention-deficit/hyperactivity disorders and intestinal disorders: A systematic review and Meta-analysis (2025) · cites this paper as [52]
Citations
Cites
Bias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722
Shea, B. J., Reeves, B. C., Wells, G., Thuku, M., Hamel, C., Moran, J., Moher, D., Tugwell, P., Welch, V., Kristjansson, E., et al. (2017) · BMJ · doi:10.1136/bmj.j4008 · Cited by 10,636
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2009.06.006 · Cited by 10,578
Sterne, J. A. C., Sutton, A. J., Ioannidis, J. P. A., Terrin, N., Jones, D. R., Lau, J., Carpenter, J., Rucker, G., Harbord, R. M., Schmid, C. H., et al. (2011) · BMJ · doi:10.1136/bmj.d4002 · Cited by 7,709
The Human Intestinal Microbiome in Health and Disease
Lynch, S. V., & Pedersen, O. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1600266 · Cited by 3,637
Nonalcoholic Fatty Liver Disease: A Systematic Review
Rinella, M. E. (2015) · JAMA · doi:10.1001/jama.2015.5370 · Cited by 2,267
The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis
Riazi, K., Azhari, H., Charette, J. H., Underwood, F. E., King, J. A., Afshar, E. E., Swain, M. G., Congly, S. E., Kaplan, G. G., & Shaheen, A.-A. (2022) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(22)00165-0 · Cited by 2,246
Non-alcoholic fatty liver disease - a global public health perspective
Younossi, Z. M. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2018.10.033 · Cited by 2,149
Intestinal barrier function: molecular regulation and disease pathogenesis
Groschwitz, K. R., & Hogan, S. P. (2009) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.05.038 · Cited by 1,775
Lactic Acid Permeabilizes Gram-Negative Bacteria by Disrupting the Outer Membrane
Alakomi, H.-L., Skyttä, E., Saarela, M., Mattila-Sandholm, T., Latva-Kala, K., & Helander, I. M. (2000) · Applied and Environmental Microbiology · doi:10.1128/aem.66.5.2001-2005.2000 · Cited by 1,093
Probiotics, Prebiotics, and Synbiotics
de Vrese, M., & Schrezenmeir, J. (2008) · Advances in Biochemical Engineering/Biotechnology · doi:10.1007/10_2008_097 · Cited by 1,028
The immune geography of IgA induction and function
Macpherson, A. J., McCoy, K. D., Johansen, F.-E., & Brandtzaeg, P. (2008) · Mucosal Immunology · doi:10.1038/mi.2007.6 · Cited by 1,028
The complex link between NAFLD and type 2 diabetes mellitus - mechanisms and treatments
Targher, G., Corey, K. E., Byrne, C. D., & Roden, M. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00448-y · Cited by 850
Probiotic bacteria and intestinal epithelial barrier function
Ohland, C. L., & MacNaughton, W. K. (2010) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00243.2009 · Cited by 801
Intestinal microbiota in patients with nonalcoholic fatty liver disease
Mouzaki, M., Comelli, E. M., Arendt, B. M., Bonengel, J., Fung, S. K., Fischer, S. E., McGilvray, I. D., & Allard, J. P. (2013) · Hepatology · doi:10.1002/hep.26319 · Cited by 749
Non alcoholic fatty liver disease and metabolic syndrome.
Paschos, P., & Paletas, K. (2009) · PubMed Central · Cited by 718
2019 Global NAFLD Prevalence: A Systematic Review and Meta-analysis
Le, M. H., Yeo, Y. H., Li, X., Li, J., Zou, B., Wu, Y., Ye, Q., Huang, D. Q., Zhao, C., Zhang, J., et al. (2022) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2021.12.002 · Cited by 711
Mack, D. R., Ahrne, S., Hyde, L., Wei, S., & Hollingsworth, M. A. (2003) · Gut · doi:10.1136/gut.52.6.827 · Cited by 666
Resta-Lenert, S., & Barrett, K. E. (2003) · Gut · doi:10.1136/gut.52.7.988 · Cited by 642
NAFLD and cardiovascular diseases: a clinical review
Kasper, P., Martin, A., Lang, S., Kütting, F., Goeser, T., Demir, M., & Steffen, H.-M. (2021) · Clinical Research in Cardiology · doi:10.1007/s00392-020-01709-7 · Cited by 632
Epithelial Barriers in Homeostasis and Disease
Marchiando, A. M., Graham, W. V., & Turner, J. R. (2010) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev.pathol.4.110807.092135 · Cited by 613
Collins, S. M., & Bercik, P. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.01.075 · Cited by 612
Liu, B.-N., Liu, X.-T., Liang, Z.-H., & Wang, J.-H. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i25.3837 · Cited by 606
Complications, morbidity and mortality of nonalcoholic fatty liver disease
Mantovani, A., Scorletti, E., Mosca, A., Alisi, A., Byrne, C. D., & Targher, G. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154170 · Cited by 553
The Biology of Intestinal Immunoglobulin A Responses
Cerutti, A., & Rescigno, M. (2008) · Immunity · doi:10.1016/j.immuni.2008.05.001 · Cited by 547
Gut microbiota and metabolic syndrome
Festi, D., Schiumerini, R., Eusebi, L. H., Marasco, G., Taddia, M., & Colecchia, A. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i43.16079 · Cited by 534
Monteiro, R. C., & van de Winkel, J. G. J. (2003) · Annual Review of Immunology · doi:10.1146/annurev.immunol.21.120601.141011 · Cited by 531
Epidemiology of non-alcoholic and alcoholic fatty liver diseases
Mitra, S., De, A., & Chowdhury, A. (2020) · Translational Gastroenterology and Hepatology · doi:10.21037/tgh.2019.09.08 · Cited by 513
The links between the gut microbiome and non-alcoholic fatty liver disease (NAFLD)
Safari, Z., & Gérard, P. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03011-w · Cited by 502
The role of Gut Microbiota in the development of obesity and Diabetes
Baothman, O. A., Zamzami, M. A., Taher, I., Abubaker, J., & Abu-Farha, M. (2016) · Lipids in Health and Disease · doi:10.1186/s12944-016-0278-4 · Cited by 493
Wehkamp, J., Harder, J., Wehkamp, K., Meissner, B. W.-V., Schlee, M., Enders, C., Sonnenborn, U., Nuding, S., Bengmark, S., Fellermann, K., et al. (2004) · Infection and Immunity · doi:10.1128/iai.72.10.5750-5758.2004 · Cited by 474
Schauber, J. (2003) · Gut · doi:10.1136/gut.52.5.735 · Cited by 383
Aller, R., de Luis, D. A., Izaola, O., Conde, R., Sagrado, M. G., Primo, D., Fuente, B. D. L., & González‐Gallego, J. (2011) · PubMed · Cited by 371
Probiotic lactobacilli and VSL#3 induce enterocyte β-defensin 2
Schlee, M., Harder, J., Köten, B., Stange, E. F., Wehkamp, J., & Fellermann, K. (2008) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.2007.03587.x · Cited by 359
Le, M. H., Yeo, Y. H., Zou, B., Barnet, S., Henry, L., Cheung, R., & Nguyen, M. H. (2022) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0239 · Cited by 357
Non-Alcoholic Fatty Liver Disease and the Metabolic Syndrome
Najjar, S. M. (2011) · Metabolic Basis of Obesity · doi:10.1007/978-1-4419-1607-5_12 · Cited by 354
Effects of probiotics on nonalcoholic fatty liver disease: A meta-analysis
Ma, Y.-Y. (2013) · World Journal of Gastroenterology · doi:10.3748/wjg.v19.i40.6911 · Cited by 352
Effects of Lactobacillus rhamnosus Strain GG in Pediatric Obesity‐related Liver Disease
Vajro, P., Mandato, C., Licenziati, M. R., Franzese, A., Vitale, D. F., Lenta, S., Caropreso, M., Vallone, G., & Meli, R. (2011) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0b013e31821f9b85 · Cited by 341
Resta–Lenert, S., & Barrett, K. E. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.12.015 · Cited by 310
Probiotics up-regulate MUC-2 mucin gene expression in a Caco-2 cell-culture model
A., M., Teitelbaum, D., R., D., F., Y., C., H., & A., C. (2002) · Pediatric Surgery International · doi:10.1007/s00383-002-0855-7 · Cited by 309
Koutnikova, H., Genser, B., Monteiro-Sepulveda, M., Faurie, J.-M., Rizkalla, S., Schrezenmeir, J., & Clément, K. (2019) · BMJ Open · doi:10.1136/bmjopen-2017-017995 · Cited by 299
Nonalcoholic Fatty Liver Disease
Adams, L. A., & Lindor, K. D. (2007) · Annals of Epidemiology · doi:10.1016/j.annepidem.2007.05.013 · Cited by 289
Effects of Probiotics on Nonalcoholic Fatty Liver Disease in Obese Children and Adolescents
Famouri, F., Shariat, Z., Hashemipour, M., Keikha, M., & Kelishadi, R. (2017) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0000000000001422 · Cited by 283
Roller, M., Rechkemmer, G., & Watzl, B. (2004) · The Journal of Nutrition · doi:10.1093/jn/134.1.153 · Cited by 280
Johnson-Henry, K. C., Hagen, K. E., Gordonpour, M., Tompkins, T. A., & Sherman, P. M. (2007) · Cellular Microbiology · doi:10.1111/j.1462-5822.2006.00791.x · Cited by 274
New Approaches for Bacteriotherapy: Prebiotics, New-Generation Probiotics, and Synbiotics
Patel, R., & DuPont, H. L. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ177 · Cited by 267
Johnson-Henry, K. C., Donato, K. A., Shen-Tu, G., Gordanpour, M., & Sherman, P. M. (2008) · Infection and Immunity · doi:10.1128/iai.00778-07 · Cited by 260
Probiotics Reduce the Inflammatory Response Induced by a High-Fat Diet in the Liver of Young Rats
Esposito, E., Iacono, A., Bianco, G., Autore, G., Cuzzocrea, S., Vajro, P., Canani, R. B., Calignano, A., Raso, G. M., & Meli, R. (2009) · The Journal of Nutrition · doi:10.3945/jn.108.101808 · Cited by 238
Scorletti, E., Afolabi, P. R., Miles, E. A., Smith, D. E., Almehmadi, A., Alshathry, A., Childs, C. E., Del Fabbro, S., Bilson, J., Moyses, H. E., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.01.031 · Cited by 237
Human gut microbiota and its relationship to health and disease: Nutrition Reviews©, Vol. 69, No. 7
Wallace, T. C., Guarner, F., Madsen, K., Cabana, M. D., Gibson, G., Hentges, E., & Sanders, M. E. (2011) · Nutrition Reviews · doi:10.1111/j.1753-4887.2011.00402.x · Cited by 234
Fang, J., Yu, C.-H., Li, X.-J., Yao, J.-M., Fang, Z.-Y., Yoon, S.-H., & Yu, W.-Y. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.997018 · Cited by 209
Treatments for NAFLD: State of Art
Mantovani, A., & Dalbeni, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22052350 · Cited by 202
Sharpton, S. R., Maraj, B., Harding-Theobald, E., Vittinghoff, E., & Terrault, N. A. (2019) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/nqz042 · Cited by 188
Gut microbiota and diabetes: From correlation to causality and mechanism
Li, W.-Z., Stirling, K., Yang, J.-J., & Zhang, L. (2020) · World Journal of Diabetes · doi:10.4239/wjd.v11.i7.293 · Cited by 185
Hrncir, T., Hrncirova, L., Kverka, M., Hromadka, R., Machova, V., Trckova, E., Kostovcikova, K., Kralickova, P., Krejsek, J., & Tlaskalova-Hogenova, H. (2021) · Microorganisms · doi:10.3390/microorganisms9050957 · Cited by 174
Ogawa, M., Shimizu, K., Nomoto, K., Tanaka, R., Hamabata, T., Yamasaki, S., Takeda, T., & Takeda, Y. (2001) · International Journal of Food Microbiology · doi:10.1016/s0168-1605(01)00465-2 · Cited by 166
Infection of T84 cells with enteropathogenic Escherichia coli alters barrier and transport functions
Philpott, D. J., McKay, D. M., Sherman, P. M., & Perdue, M. H. (1996) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.1996.270.4.g634 · Cited by 161
Möndel, M., Schroeder, B. O., Zimmermann, K., Huber, H., Nuding, S., Beisner, J., Fellermann, K., Stange, E. F., & Wehkamp, J. (2009) · Mucosal Immunology · doi:10.1038/mi.2008.77 · Cited by 157
NAFLD — sounding the alarm on a silent epidemic
Lazarus, J. V., Colombo, M. G., Cortez‐Pinto, H., Huang, T. T. ‐., Miller, V., Ninburg, M. H., Schattenberg, J. M., Seim, L., Wong, V. W., & Zelber‐Sagi, S. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-0315-7 · Cited by 157
Loman, B. R., Hernández-Saavedra, D., An, R., & Rector, R. S. (2018) · Nutrition Reviews · doi:10.1093/nutrit/nuy031 · Cited by 147
Kim, Y., Kim, S. H., Whang, K. Y., Kim, Y. J., & Oh, S. (2008) · PubMed · Cited by 142
Ogawa, M., Shimizu, K., Nomoto, K., Takahashi, M., Watanuki, M., Tanaka, R., Tanaka, T., Hamabata, T., Yamasaki, S., & Takeda, Y. (2001) · Infection and Immunity · doi:10.1128/iai.69.2.1101-1108.2001 · Cited by 139
Wu, X., Vallance, B. A., Boyer, L., Bergstrom, K. S. B., Walker, J., Madsen, K., O'Kusky, J. R., Buchan, A. M., & Jacobson, K. (2008) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00173.2007 · Cited by 137
Defensins in the immunology of bacterial infections
Menéndez, A., & Finlay, B. B. (2007) · Current Opinion in Immunology · doi:10.1016/j.coi.2007.06.008 · Cited by 131
Fedwick, J. P., Lapointe, T. K., Meddings, J. B., Sherman, P. M., & Buret, A. G. (2005) · Infection and Immunity · doi:10.1128/iai.73.12.7844-7852.2005 · Cited by 129
The gastric mucus layers: constituents and regulation of accumulation
Phillipson, M., Johansson, M. E. V., Henriksnäs, J., Petersson, J., Gendler, S. J., Sandler, S., Persson, A. E. G., Hansson, G. C., & Holm, L. (2008) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.90252.2008 · Cited by 126
Malaguarnera, M., Gargante, M. P., Malaguarnera, G., Salmeri, M., Mastrojeni, S., Rampello, L., Pennisi, G., Volti, G. L., & Galvano, F. (2010) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0b013e328330a8d3 · Cited by 119
Yari, Z., Rahimlou, M., Eslamparast, T., Ebrahimi-Daryani, N., Poustchi, H., & Hekmatdoost, A. (2016) · International Journal of Food Sciences and Nutrition · doi:10.3109/09637486.2016.1161011 · Cited by 118
Duquesne, S., Petit, V., Peduzzi, J., & Rebuffat, S. (2007) · Microbial Physiology · doi:10.1159/000104748 · Cited by 108
LeBlanc, J., Fliss, I., & Matar, C. (2004) · Clinical and Vaccine Immunology · doi:10.1128/cdli.11.6.1171-1181.2004 · Cited by 106
Liu, L., Li, P., Liu, Y., & Zhang, Y. (2019) · Digestive Diseases and Sciences · doi:10.1007/s10620-019-05699-z · Cited by 104
Gao, X., Zhu, Y., Wen, Y., Liu, G., & Wan, C. (2016) · Hepatology Research · doi:10.1111/hepr.12671 · Cited by 97
Perspectives on Treatment for Nonalcoholic Steatohepatitis
Lassailly, G., Caiazzo, R. J., Pattou, F. N., & Mathurin, P. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.03.004 · Cited by 94
Hadi, A., Mohammadi, H., Miraghajani, M., & Ghaedi, E. (2019) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2018.1458021 · Cited by 94
Suzumura, E. A., Bersch-Ferreira, Â. C., Torreglosa, C. R., da Silva, J. T., Coqueiro, A. Y., Kuntz, M. G. F., Chrispim, P. P., Weber, B., & Cavalcanti, A. B. (2019) · Nutrition Reviews · doi:10.1093/nutrit/nuz001 · Cited by 85
Effects of probiotics on nonalcoholic fatty liver disease: a systematic review and meta-analysis
Tang, Y., Huang, J., Zhang, W. Y., Qin, S., Yang, Y. X., Ren, H., Yang, Q.-B., & Hu, H. (2019) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756284819878046 · Cited by 85
Systematic Review with Meta-Analysis: The Effects of Probiotics in Nonalcoholic Fatty Liver Disease
Xiao, M.-W., Lin, S.-X., Shen, Z.-H., Luo, W.-W., & Wang, X.-Y. (2019) · Gastroenterology Research and Practice · doi:10.1155/2019/1484598 · Cited by 84
Pan, X., Wen, S. W., Kaminga, A. C., & Liu, A. (2020) · Scientific Reports · doi:10.1038/s41598-020-65051-8 · Cited by 79
Innate and adaptive mechanisms to control of pathological intestinal inflammation
Kelsall, B. (2008) · The Journal of Pathology · doi:10.1002/path.2286 · Cited by 77
Synthesis and secretion of mucin by the human colonic tumour cell line LS180
McCool, D., Forstner, J., & Forstner, G. (1994) · Biochemical Journal · doi:10.1042/bj3020111 · Cited by 70
Role of Probiotics in the Treatment of Nonalcoholic Fatty Liver Disease: A Meta-analysis
Lavekar, A. S., Raje, D. V., & Lavekar, A. A. (2017) · Euroasian Journal of Hepato-Gastroenterology · doi:10.5005/jp-journals-10018-1233 · Cited by 67
Kupčová, V., Fedelešová, M., Bulas, J., Kozmonová, P., & Turecký, L. (2019) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph16193570 · Cited by 54
Stachowska, E., Portincasa, P., Jamioł-Milc, D., Maciejewska-Markiewicz, D., & Skonieczna-Żydecka, K. (2020) · Nutrients · doi:10.3390/nu12113460 · Cited by 54
Khan, M. Y., Mihali, A. B., Rawala, M. S., Aslam, A., & Siddiqui, W. J. (2019) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000001371 · Cited by 52
Role of the microbiota in hypertension and antihypertensive drug metabolism
Mishima, E., & Abe, T. (2021) · Hypertension Research · doi:10.1038/s41440-021-00804-0 · Cited by 52
The role of epithelial malfunction in the pathogenesis of enteropathogenic E. coli-induced diarrhea
Lapointe, T. K., O’Connor, P. M. J., & Buret, A. G. (2009) · Laboratory Investigation · doi:10.1038/labinvest.2009.69 · Cited by 47
Effect of Probiotics Therapy on Nonalcoholic Fatty Liver Disease
Huang, Y., Wang, X., Zhang, L., Zheng, K., Xiong, J., Li, J., Cong, C., Gong, Z., & Mao, J. (2022) · Computational and Mathematical Methods in Medicine · doi:10.1155/2022/7888076 · Cited by 44
Effects of probiotics on nonalcoholic fatty liver disease: a systematic review and meta-analysis
Yang, R., Shang, J., Zhou, Y., Liu, W., Tian, Y., & Shang, H. (2021) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2022.2016391 · Cited by 43
Chung, G. E., Yim, J. Y., Kim, D., Kwak, M., Yang, J. I., Chung, S. J., Yang, S. Y., & Kim, J. S. (2016) · Gastroenterology Research and Practice · doi:10.1155/2016/7653689 · Cited by 39
NASH: A glance at the landscape of pharmacological treatment.
Brodosi, L., Marchignoli, F., Petroni, M. L., & Marchesini, G. (2016) · PubMed · doi:10.5604/16652681.1212318 · Cited by 38
Tomson, F. L., Koutsouris, A., Viswanathan, V. K., Turner, J. R., Savkovic, S. D., & Hecht, G. A. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.06.014 · Cited by 33
Non-alcoholic fatty liver disease in diabetes: When to refer to the hepatologist?
Khandelwal, R., Dassanayake, A. S., Conjeevaram, H. S., & Singh, S. P. (2021) · World Journal of Diabetes · doi:10.4239/wjd.v12.i9.1479 · Cited by 29
Gkiourtzis, Ν., Kalopitas, G., Vadarlis, A., Bakaloudi, D. R., Dionysopoulos, G., Karanika, E., Tsekitsidi, E., & Chourdakis, M. (2022) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0000000000003537 · Cited by 27
Amini‐Salehi, E., Hassanipour, S., Joukar, F., Daryagasht, A. A., Khosousi, M., Aleali, M. S., Ansar, M. M., Heidarzad, F., Abdzadeh, E., Vakilpour, A., et al. (2023) · Hepatitis Monthly · doi:10.5812/hepatmon-131523 · Cited by 23
Self-citationMasselot, C. R., Herrmann, A., Carlstedt, I., Michalski, J., & Capon, C. (2007) · Glycoconjugate Journal · doi:10.1007/s10719-007-9079-3 · Cited by 20
Cited by
Amini-Salehi, E., Letafatkar, N., Norouzi, N., Joukar, F., Habibi, A., Javid, M., Sattari, N., Khorasani, M., Farahmand, A., Tavakoli, S., et al. (2024) · Archives of Medical Research · doi:10.1016/j.arcmed.2024.103043 · Cited by 171
Self-citationSaeed, H., Díaz, L. A., Gil‐Gómez, A., Burton, J. P., Bajaj, J. S., Romero‐Gómez, M., Arrese, M. A., Arab, J. P., & Khan, M. Q. (2024) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2024.0811 · Cited by 91
Recent advances in therapeutic probiotics: insights from human trials
Cho, M.-Y., Eom, J.-H., Choi, E.-M., Yang, S., Lee, D., Kim, Y.-Y., Kim, H.-S., & Hwang, I. (2025) · Clinical Microbiology Reviews · doi:10.1128/cmr.00240-24 · Cited by 58
Yogesh, M., Patel, M., Gandhi, R. B., Patel, A. M., & Kidecha, K. N. (2025) · BMC Endocrine Disorders · doi:10.1186/s12902-025-01935-y · Cited by 46
Vakilpour, A., Amini‐Salehi, E., Moghadam, A. S., Keivanlou, M., Letafatkar, N., Habibi, A., Hashemi, M., Eslami, N., Zare, R., Norouzi, N., et al. (2024) · Nutrition and Diabetes · doi:10.1038/s41387-024-00281-7 · Cited by 35
Self-citation
Metadata
- Authors
- Amini-Salehi, E., Hassanipour, S., Keivanlou, M.-H., Shahdkar, M., Orang Goorabzarmakhi, M., Vakilpour, A., Joukar, F., Hashemi, M., Sattari, N., Javid, M., & Mansour-Ghanaei, F.
- Affiliations
- Gastrointestinal and Liver Diseases Research Center, Guilan University of Medical Sciences , Rasht, Iran
- Guilan University of Medical Sciences (IR)
- School of Medicine, Guilan University of Medical Sciences , Rasht, Iran
- Hormozgan University of Medical Sciences (IR)
- ORCID
- Venue
- Nutrition Reviews
- Publisher
- Oxford University Press (OUP)
- Published
- 2023-08-07
- Volume
- 82
- Issue
- 6
- Pages
- 815-830
- ISSN
- 0029-6643 (ISSN-L)
- 1753-4887
- OpenAlex
- W4385621532
- Cited by
- 42
- References
- 96
- Citations by year
- 2026: 8 · 2025: 18 · 2024: 16
- FWCI
- 1.63
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Nutrition Reviews (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Keywords
- non-alcoholic fatty liver disease, probiotics, prebiotics, synbiotics, liver enzymes, alanine aminotransferase, aspartate aminotransferase, gamma-glutamyl transferase, NAFLD treatment, evidence quality assessment, AMSTAR 2, subgroup analysis
- MeSH terms
- Gastrointestinal Microbiome, Alanine Transaminase, Aspartate Aminotransferases, Humans, Liver, Probiotics, Prebiotics, Synbiotics, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.